TY - JOUR
T1 - Future scenarios for the treatment of advanced non-small cell lung cancer
T2 - Focus on taxane-containing regimens
AU - Grossi, Francesco
AU - Kubota, Kaoru
AU - Cappuzzo, Federico
AU - De Marinis, Filippo
AU - Gridelli, Cesare
AU - Aita, Marianna
AU - Douillard, Jean Yves
PY - 2010/10
Y1 - 2010/10
N2 - Despite recent progress in the development of new molecularly targeted agents, the chemotherapy regimens considered standard at the end of the last century-that is, two-drug combinations consisting of either cisplatin or carboplatin plus a third-generation agent (docetaxel, paclitaxel, gemcitabine, or vinorelbine)-remain the primary treatment option for advanced non-small cell lung cancer (NSCLC) patients. Most recently, the existing standard of care has been amended to reflect the significant survival advantage of cisplatin-pemetrexed over cisplatin- gemcitabine as first-line treatment of nonsquamous NSCLC. The addition of a biological drug (bevacizumab, cetuximab) or the use of a singleagent epidermal growth factor receptor inhibitor may further improve outcomes in selected patients. It has become increasingly clear, primarily through recent meta-analyses, that although the therapeutic equivalence of any combination of a platinum agent plus either gemcitabine, vinorelbine, docetaxel, or paclitaxel has been long accepted, each regimen has different side effects and therapeutic outcomes that allow clinicians to select the most appropriate treatment for chemotherapy- naïve patients with stage IIIB/IV NSCLC. In this review, we evaluate the available evidence and explore the role and importance of various modern chemotherapy regimens, with the aim of optimizing treatment selection and combination with biological agents. Emphasis is placed on the role of taxanes (docetaxel versus paclitaxel) in this changing landscape.
AB - Despite recent progress in the development of new molecularly targeted agents, the chemotherapy regimens considered standard at the end of the last century-that is, two-drug combinations consisting of either cisplatin or carboplatin plus a third-generation agent (docetaxel, paclitaxel, gemcitabine, or vinorelbine)-remain the primary treatment option for advanced non-small cell lung cancer (NSCLC) patients. Most recently, the existing standard of care has been amended to reflect the significant survival advantage of cisplatin-pemetrexed over cisplatin- gemcitabine as first-line treatment of nonsquamous NSCLC. The addition of a biological drug (bevacizumab, cetuximab) or the use of a singleagent epidermal growth factor receptor inhibitor may further improve outcomes in selected patients. It has become increasingly clear, primarily through recent meta-analyses, that although the therapeutic equivalence of any combination of a platinum agent plus either gemcitabine, vinorelbine, docetaxel, or paclitaxel has been long accepted, each regimen has different side effects and therapeutic outcomes that allow clinicians to select the most appropriate treatment for chemotherapy- naïve patients with stage IIIB/IV NSCLC. In this review, we evaluate the available evidence and explore the role and importance of various modern chemotherapy regimens, with the aim of optimizing treatment selection and combination with biological agents. Emphasis is placed on the role of taxanes (docetaxel versus paclitaxel) in this changing landscape.
KW - Chemotherapy
KW - Docetaxel
KW - Non-small cell lung carcinoma
KW - Treatment algorithm
UR - http://www.scopus.com/inward/record.url?scp=77958566257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958566257&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2010-0322
DO - 10.1634/theoncologist.2010-0322
M3 - Article
C2 - 20930102
AN - SCOPUS:77958566257
VL - 15
SP - 1102
EP - 1112
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 10
ER -